These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6113065)

  • 1. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
    Steinmetz J; Morin C; Panek E; Siest G; Drouin P
    Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.
    Liang B; McMaster JC; Kroeger EA; Hatch GM; Mymin D; Dembinski T; Arthur G; Shen G; Man RY; Choy PC
    Mol Cell Biochem; 2000 Apr; 207(1-2):123-9. PubMed ID: 10888237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on fenofibrate.
    Brown WV
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():31-40. PubMed ID: 3134383
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
    Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.
    Noguchi Y; Tatsuno I; Suyama K; Shibata T; Yoshida T; Otsuka Y; Fuse M; Takeo C; Saito Y
    J Atheroscler Thromb; 2004; 11(6):335-40. PubMed ID: 15644587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
    Tesone PA; Gladstein J; Acuña AM
    Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of fenofibrate and clofibrate hypolipidemic effects.
    Daubresse JC
    Acta Clin Belg; 1980; 35(4):227-32. PubMed ID: 7015771
    [No Abstract]   [Full Text] [Related]  

  • 10. Monocyte suppressing action of fenofibrate.
    Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
    Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and metabolic effects of pentaerythritol tetranicotinate(Perycit)and a comparison with plain nicotinic acid.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1974; 19(1):61-73. PubMed ID: 4359183
    [No Abstract]   [Full Text] [Related]  

  • 12. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
    Li LJ; Chen H; Ren JY; Wang L; Luo Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
    Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
    J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of combined hyperlipidaemia and its treatment with fenofibrate.
    Superko HR
    J Int Med Res; 1989; 17(2):99-112. PubMed ID: 2656334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.